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| INTRODUCTION
Currently available biological drugs are large proteins, often monoclonal antibodies, which bind and inhibit a target molecule.
Anti-tumour necrosis factor (TNF) agents, including infliximab and adalimumab, were the first biological agents effective in inducing and maintain remission in inflammatory bowel disease (IBD). [1] [2] [3] [4] More recently developed biological agents effective in IBD include vedolizumab, an a4b7-integrin inhibitor, and ustekinumab, an inhibitor of the inflammatory cytokines interleukin-12/23.
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Although biological agents have revolutionised IBD treatment, primary nonresponse and secondary loss-of-response are common with resulting adverse outcomes. Among infliximab-and adalimumab-treated patients, primary nonresponse occurs in 10%-30% of patients, and secondary loss-of-response in 23%-46% by 12 months. 3, 4, 8, 9 Treatment with biological agents is expensive and there are limited biological drug choices for IBD, highlighting a need to optimally use each agent. Therapeutic drug monitoring (TDM)-guided anti-TNF dosing has emerged as a strategy to optimise treatment and maximise benefits from these drugs. TDM for anti-TNF agents involves measurement of drug levels and anti-drug antibodies.
Reactive TDM is performed in patients failing treatment in order to guide decision-making. Proactive TDM is performed in responding patients to optimise therapy and potentially prevent future flare and loss-of-response. Data for TDM-guided dosing are emerging for other biological agents. [10] [11] [12] [13] We employed a modified Delphi method to reach a consensus for incorporating TDM for anti-TNF agents into modern IBD management. [14] [15] [16] [17] [18] [19] Points addressed included scenarios for performing TDM, interpretation of results and when/how to act on them. We focused on TDM for anti-TNF agents as this has the largest evidence base to date.
| ME TH ODS
A modified Delphi process with 3 iterations was employed in developing these guidelines as previously described. 20 (Tables 1-3 ). There was significant correlation between NHMRC evidence level and grade of recommendation (Spearman's correlation co-efficient = 0.544, P = .006).
| Scenarios when TDM of anti-TNF agents should be performed
The following statements are scenarios that benefit from TDM. An additional indication to a previous consensus, TDM might identify immunogenicity on reintroduction of a biological agent after previous exposure. 22 Detectable antibodies to infliximab (ATI) during infliximab reintroduction, particularly high titres, are associated with an increased risk of subsequent infusion reactions. 23 Transient ATI on infliximab reintroduction, however, are common and not associated with infusion reactions in most patients. [23] [24] [25] There is no clear ATI titre cut-off that predicts for reactions with adequate power. Discontinuing patients with anti-drug antibodies following anti-TNF reintroduction who are otherwise responding, may result in more futile treatment changes than prevented drug reactions.
1. In patients in clinical remission following anti-TNF therapy induction, TDM should be considered to guide management (EL-II,
RG-C).
Sub-therapeutic adalimumab and infliximab drug levels are associated with increased future risk of developing anti-drug antibodies and increased disease activity. 22, [26] [27] [28] [29] [30] [31] The risk of ATI increased with the duration of the sub-therapeutic drug levels. 31 TDM shortly following successful induction therapy may identify patients with sub-therapeutic drug levels. Dose intensification to achieve therapeutic drug levels may reduce the risk of developing anti-drug antibodies and secondary loss-of-response, particularly as most anti-drug antibodies develop in the first 12 months from starting therapy. [32] [33] [34] During the lead-in optimisation phase of the Trough level Adapted infliXImab Treatment (TAXIT) trial, patients with Crohn's disease (CD) who had sub-therapeutic drug levels underwent dose intensification to achieve a target range (3-7 lg/ mL); this was associated with a decrease in mean C-reactive protein (CRP) and increase in the proportion of patients in clinical remission. 35, 36 No statistically significant difference was found for UC patients. The median time from first infliximab exposure to recruitment to the TAXIT trial was 4.5 years, and potentially there may be more to gain from earlier dose optimisation. Alternatively, a longer duration of follow-up might have detected a divergence in loss-of-response.
TDM can inform clinical decision-making in patients with primary nonresponse (EL-III2, RG-C).
There is good evidence supporting the role of TDM in secondary T A B L E 2 Interpreting TDM results (Statements 7-16). Acceptance was defined by percentage agreement with no or only minor reservation. Statements that did not meet criteria for consensus are marked with "*". The NHMRC evidence levels (EL) and recommendation grades (RG) are described Objective assessment of disease activity should be used in addition to symptoms in a "treat-to-target" management approach. 58, 59 Only half of CD patients considered to be in clinical remission are found to have mucosal healing, and faecal calprotectin is a more accurate predictor of mucosal healing in CD than clinical assessment using the Crohn's Disease Activity Index (CDAI). 60, 61 Bowel symptoms may not correlate with endoscopic-or serum/faecal biomarker -evidence of inflammation. [62] [63] [64] [65] [66] As such, non-inflammatory causes of symptoms, such as intestinal stricture, bile salt malabsorption, malignancy, small bowel bacterial overgrowth, dietary intolerances or overlapping irritable bowel syndrome (IBS) need to be considered. 64 Up to 60% of IBD patients with ongoing bowel symptoms have mucosal healing. [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] A normal faecal calprotectin in the context of underlying IBD and ongoing bowel symptoms has high predictive value for functional gut disorder or impaired intestinal permeability. 66, 75 Infective colitis with C. difficile and cytomegalovirus should also be excluded. out-of-class was associated with significantly improved outcomes. 39 , 64 Roblin et al found that those with an adalimumab level ≥4.9 lg/mL had lower response rates when switched to infliximab than those whose adalimumab levels were <4.9 lg/mL. 40 Because of the limited biological agents currently available, completely exhausting one biological drug before switching to another is recommended. 47 Due to wide inter-individual variability in the minimal drug level required for response, patients with treatment failure and drug levels within the therapeutic range may still benefit from dose intensification, although likelihood of this dramatically decreases with increasing pre-dose intensification drug levels. For example, an IBD patient with history of aggressive disease, prior failure to multiple treatments and an infliximab trough of 8 lg/mL may still be appropriate for a trial of dose intensification. Achieving remission is the endpoint of treatment with anti-TNF biological drugs rather than achieving a specific drug level. Anti-drug antibody titre can influence the response to a change in management. Low-titre anti-drug antibodies may be overcome with dose escalation to restore therapeutic drug levels and response. 39 The addition of methotrexate or a thiopurine can also overcome anti-drug antibodies. patients in clinical remission were summarised in an algorithm (Figure 2) .
Patients in clinical remission and with therapeutic trough
drug levels should be continued on the same dose (EL-II, RG-B).
The above statement assumes the therapeutic range chosen is appropriate for the treatment endpoint.
12. Patients in clinical remission and with supra-therapeutic trough drug levels should be considered for dose reduction (EL-III1,
RG-B).
Due to limited incremental clinical benefit of targeting anti-TNF trough concentrations above a certain threshold, significant cost saving can be achieved by dose reducing patients with supra-therapeutic levels without worsening clinical outcomes. As previously discussed, low-titre anti-drug antibodies can be overcome with anti-TNF dose escalation or addition of an immunomodulator to restore therapeutic anti-TNF drug levels. 39, 97, 98 This has predominantly been demonstrated among patients with loss-of-response but likely still applies for patients in clinical remission.
Patients in clinical remission who have high-risk features
with undetectable trough drug levels and persistently high titres of anti-drug antibodies should be considered for switching within or
out-of-class (EL-III2, RG-C).
Anti-TNF dose intensification or immunomodulator addition are unlikely to eliminate persistent high-titre anti-drug antibodies to restore therapeutic anti-TNF drug levels. 39, 102 Although high-titre anti-drug antibodies are associated with persistence of antibodies, there may be less urgency to change treatment in asymptomatic patients, and repeat testing to exclude anti-drug antibody transiency may still be worthwhile before switching to another biological agent.
| Target drug trough levels
It is unclear if trough levels are the best predictor of response to anti-TNF agents, compared to peak drug levels, drug levels at other points of the dosing cycle or total drug exposure as defined by area under a concentration-time graph. 81 The committee considered several factors in agreeing on a therapeutic range. Most TDM data, particularly for adalimumab, are for luminal CD patients; however, studies among UC patients have found similar cut-offs. 47 The defined therapeutic ranges for adalimumab and infliximab should be applied with a degree of caution to UC patients. Anti-TNF drug levels do not correlate with risk of side effects. 47, [85] [86] [87] 119 Hence, a therapeutic range should focus on optimising clinical efficacy rather than avoiding toxicity. 47, 81 Studies have found that responders have higher infliximab levels than nonresponders. [134] [135] [136] [137] [138] Several have defined an infliximab therapeutic cut-off or range that is associated with a specific endpoint. 29, 35, 39, 42, 47, 106, 107, 134, 135, [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] In a retrospective study of secondary loss-of-response in IBD, a pre-dose intensification infliximab trough of ≥3.4 lg/mL was 90% specific for failure to recapture response. 39 18. In IBD patients with luminal disease, a steady-state trough adalimumab level between 5 and 12 lg/mL is generally recom-
mended (EL-II, RG-C).
Data supporting a therapeutic cut-off or range for adalimumab for various endpoints have also been reported. 27, [39] [40] [41] 47, 106, 139, [153] [154] [155] [156] [157] [158] [159] [160] [161] Among patient with secondary loss-of-response, Yanai et al found a pre-dose intensification adalimumab drug level of ≥4.5 lg/mL to be 90% specific for failure to respond. 39 Immediately following induction therapy, a cross-sectional study found a week 14 adalimumab trough level of >4.5 lg/mL to be associated with clinical response or remission. 28, 139 Rheumatological studies show that response plateaus above an adalimumab trough of 7-8 lg/mL. 162, 163 The upper limit of the adalimumab therapeutic range to achieve clinical remission in IBD is poorly defined, but endoscopic remission rates plateau above a trough level of 12 lg/mL. 106 19. In certain situations, higher or lower trough levels than the above ranges may be appropriate (EL-III3, RG-B).
Therapeutic ranges for infliximab or adalimumab may differ according to treatment targets and/or disease phenotypes. Therapeutic thresholds to achieve endoscopic remission appear to be higher than those required for clinical remission. 47 Therapeutic ranges of 6-10 lg/mL for infliximab and 8-12 lg/mL for adalimumab were most strongly associated with endoscopic remission. 106 Perianal CD fistula healing requires higher infliximab trough levels of >10 lg/mL, and even as high as 20 lg/mL.
164,165
3.7 | Anti-drug antibodies 20 . When interpreting anti-drug antibodies, quantifying titres is clinically more useful than positive/negative status (EL-II, RG-B0).
Anti-drug antibodies can interfere with the activity of anti-TNF agents by increasing drug clearance and by direct neutralisation. 89, 90, 166, 167 Qualitative detection of antibodies to adalimumab (ATA) and ATI is associated with sub-therapeutic drug trough levels, loss-of-response and lack of recapture of response following dose escalation. 40, [168] [169] [170] However, quantification of the anti-drug antibody level is a better predictor. 23, 39, 154, 171 Low-titre anti-drug antibodies can often be overcome with dose intensification, and do not appear to reduce the likelihood of response as compared to patients with undetectable anti-drug antibodies. 39 Differences in assay methodology result in varying sensitivity to detect various anti-drug antibody subtypes, and adjusting for these differences is difficult due to a wide variation in the relative proportions of anti-drug antibody subtypes between individuals. 125, 126, 172, 173 Therefore, ATI and ATA cut-offs are assay specific.
When interpreting anti-drug antibodies, repeat testing is useful to determine if antibodies are transient or persistent (EL-II, RG-B).
Anti-drug antibodies can be transient and can disappear on repeat testing. Such transient anti-drug antibodies, particularly ATI, are common and not associated with loss-of-response or failure to respond to dose intensification, unlike persistent anti-drug antibodies. 25, 174, 175 The presence of ATI on 2 consecutive blood samples ≥2 months apart was associated with subsequent loss-of-response.
Initially, high titres of ATI do not consistently predict for antibody persistence. 102, 175 Although ATA tend to occur at lower rates, they appear to have a higher rate of persistence and, in turn, greater chance of loss-of-response compared with ATI. 25, 34, 173 Once ATI or ATA are detected, repeat testing at a later time point to differentiate transient from persistent antibodies is recommended where appropriate. Repeat testing to confirm anti-drug antibody persistence may also be appropriate for patients with high initial titres, particularly for those responding to therapy in whom the next step would be switching therapy. Other scenarios, such as severe active symptoms, may require a prompt change in therapy without delay in repeat testing.
There is insufficient evidence to recommend a drug-tolerant assay for anti-drug antibody detection (EL-III1, RG-C).
Assays for measuring anti-TNF drug and anti-drug antibody levels can be broadly divided into drug-tolerant or drug-sensitive, depending on their capacity to detect anti-drug antibodies in the presence of drug. [176] [177] [178] Drug-sensitive assays are less expensive, and are commonly enzyme-linked immunosorbent assays (ELISA) or radio-immunoassays (RIA). Drug-tolerant assays include the homogeneous mobility-shift assay (HMSA) and the electrochemiluminescence immunoassay. 176, 177, 179 Recently, drug-tolerant ELISAs and
RIAs which include an acid-disassociation step to separate free drug from bound anti-drug antibody prior to total anti-drug antibody detection have been reported. 81, 180 Detection of anti-drug antibodies in the presence of therapeutic anti-TNF drug levels does not appear to provide an advantage. Most anti-drug antibodies detected via the HMSA lack neutralising potential when tested via a functional cell-based reporter-gene assay, which infers they may not be clinically significant. 126 Although detectable ATI in the presence of therapeutic infliximab levels have been associated with higher CRP levels, in another study they were not associated with lack of response to dose intensification. for ATI via a drug-tolerant assay as opposed to 21% via a drug-sensitive assay. 182 For the drug-tolerant assay, only ATI titres in the highest quartile were associated with a need for higher infliximab doses to achieve therapeutic infliximab concentrations, and all except one of these patients were also detected as ATI positive via the drug-sensitive assay. This is evidence against the benefit of drug-tolerant assays over drug-sensitive assays.
3.8 | TDM for non-anti-TNF biological agents and future therapies 23 . There is emerging evidence that drug levels of non-anti-TNF biological agents may be relevant to clinical endpoints. However, more data are required before the routine use of TDM to guide therapy with these agents can be recommended (EL-IV, RG-D).
There are limited data for TDM of non-anti-TNF biological agents in IBD. However, there is no reason why the general pharmacokinetic principle of response being related to exposure would not apply. Higher vedolizumab drug levels are associated with higher rates of clinical and endoscopic remission in UC. 10, 11 Rates of mucosal healing were higher with increasing vedolizumab drug level quartiles at week 6 in a small cross-sectional study. A week 6
vedolizumab drug level threshold of <19.0 lg/mL was found to be MITREV ET AL.
| 1045 predictive of subsequent dose escalation for lack of response, and dose escalation was successful in inducing clinical remission in this setting. 183 Of note, vedolizumab completely saturates the a4b7 receptor at serum levels of 1 lg/mL in vitro. However at such concentrations in vivo, efficacy is no different to placebo inferring that the pharmacokinetic-pharmacodynamic relationship with vedolizumab might be different to that observed with anti-TNF therapy. 184 Higher ustekinumab drug levels were also associated with greater rates of clinical remission. 12 Week 8 ustekinumab trough levels >4.5 and >5 lg/mL are also associated with endoscopic response and CRP normalisation respectively. 13 In psoriasis, in contrast, ustekinumab levels did not correlate with clinical response. 185 3.9 | Statements that did not reach consensus 13 . Patients in clinical remission and with sub-therapeutic drug trough levels should be individually assessed for suitability for a drug holiday (EL-III3, RG-C).
Anti-TNF drug holiday should not be considered for a patient purely based on an unexpected finding of sub-therapeutic drug trough levels during proactive TDM. This is in agreement with statement 4 that a routine TDM interval for patients in clinical remission
is not recommended and that TDM should only be performed if results will alter management. There are limitations to these statements. Firstly, these therapeutic ranges were for clinical remission as the endpoint, which is emphasised by the Australian pharmaceutical funding body. There is emerging evidence that mucosal healing beyond symptoms might require higher trough drug levels. 106 VK has no personal interests to declare. PL has served as a speaker and advisory board member for Abbvie and Janssen. JM has no personal interests to declare. RM has served as a speaker for Janssen.
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